Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Veteran Mental Health Initiatives

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction on April 28, 2026, to its earlier release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs but reaffirms the collaboration's goal to support Phase 3 recruitment for its HLP003 program in major depressive disorder and expand outreach in veteran communities. The partnership aligns with a recent executive order aimed at advancing mental health treatments and clinical research participation.

Helus Pharma, the commercial operating name of Cybin Inc., is focused on developing proprietary NSAs—novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These treatments aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions.

The correction comes as Helus Pharma continues to advance its clinical programs and partnerships. The TARA Mind collaboration is expected to facilitate patient recruitment for the Phase 3 trial, leveraging TARA Mind's network to reach veteran communities. The company's efforts are in line with broader policy initiatives to improve mental health care access and clinical trial participation.

Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website at www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The full press release is available at https://ibn.fm/re8HL.

InvestorWire, a specialized communications platform, disseminated this press release. For more information, visit https://www.InvestorWire.com.